FDA Approval for Pediatric Use
Remicade (infliximab) is FDA-approved for children ages 6 and older with moderate to severe Crohn's disease, including those who haven't responded to conventional therapy.[1][2] It's also approved for kids 6+ with moderately to severely active polyarticular juvenile idiopathic arthritis (JRA) when methotrexate alone isn't enough.[1] The agency requires a Risk Evaluation and Mitigation Strategy (REMS) program due to risks like serious infections and malignancy.[2]
Common Side Effects in Kids
Kids on Remicade often experience upper respiratory infections, headache, nausea, abdominal pain, fever, and infusion reactions like rash or itching.[1][3] In pediatric Crohn's trials, 74% of children had adverse events, with 23% serious; infections affected 38%.[3] Monitoring includes TB screening before starting and regular checks for infections.[2]
Serious Risks and Warnings
Remicade suppresses the immune system, raising infection risks (e.g., pneumonia, sepsis) that can be fatal—seen in 3% of pediatric Crohn's patients in studies.[3] It carries black box warnings for active infections, increased lymphoma and skin cancer risk (hepatosplenic T-cell lymphoma reported in young males with IBD on TNF blockers + thiopurines), heart failure worsening, and hepatitis B reactivation.[1][2][4] No increased TB risk in controlled pediatric trials, but real-world data shows higher opportunistic infections.[3]
Long-Term Safety Data
In a 54-week extension study of 60 kids with Crohn's, Remicade maintained efficacy, but 57% had infections; one case each of serious pneumonia and abscess occurred.[3] Lymphoma risk is higher with combination therapy (azathioprine or 6-MP); avoid if possible.[4] Growth suppression or delayed puberty isn't directly linked, but monitor development.[2] Janssen recommends weighing benefits against risks, with lowest effective dose.[1]
Who Should Avoid It
Not for kids under 6, those with active infections, heart failure, or recent live vaccines.[2] Use caution in demyelinating disorders (e.g., MS history) due to rare worsening.[1] Breastfeeding data is limited; benefits may outweigh risks, but monitor infant for infections.[2]
[1] FDA Label for Remicade
[2] FDA REMS for TNF Blockers
[3] REACH Pediatric Crohn's Study (NEJM, 2007)
[4] FDA Drug Safety Communication on Lymphomas (2009)